Jamjoom Pharmaceuticals Factory Co. vs Middle East Pharmaceutical Industries Company
A head-to-head of Jamjoom Pharmaceuticals Factory Co. (4015) and Middle East Pharmaceutical Industries Company (4016) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
Jamjoom Pharmaceuticals Factory Co.
4015
146.90 SAR
-1.34%
VS
Middle East Pharmaceutical Industries Company
4016
60.45 SAR
-0.74%
| Metric | 4015 | 4016 |
|---|---|---|
| Market Cap | 11.05B SAR | 2.06B SAR |
| P/E (TTM) | 22.16 | 12.46 |
| Forward P/E | — | 11.57 |
| P/S | 7.25 | 4.19 |
| P/B | 5.95 | 5.07 |
| EV/EBITDA | 20.41 | 9.59 |
| Dividend Yield | 253.00% | 2.39% |
| Profit Margin | 31.16% | 21.19% |
| Gross Margin | 62.56% | 62.29% |
| Operating Margin | 31.82% | 23.74% |
| Revenue Growth (YoY) | +5.21% | +33.65% |
| FCF Yield | 2.33% | 1.62% |
| Debt / Equity | 1.20 | 19.87 |
| Current Ratio | 4.94 | 2.85 |
Which is better: Jamjoom Pharmaceuticals Factory Co. or Middle East Pharmaceutical Industries Company?
- ✓Larger by market cap: Jamjoom Pharmaceuticals Factory Co.
- ✓Cheaper valuation (lower P/E): Middle East Pharmaceutical Industries Company
- ✓Higher dividend yield: Jamjoom Pharmaceuticals Factory Co.
- ✓More profitable (net margin): Jamjoom Pharmaceuticals Factory Co.
- ✓Faster revenue growth: Middle East Pharmaceutical Industries Company
- ✓Higher free-cash-flow yield: Jamjoom Pharmaceuticals Factory Co.
Across 12 available metrics, Jamjoom Pharmaceuticals Factory Co. leads 7–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Jamjoom Pharmaceuticals Factory Co. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.